NETRIS PHARMA
About the company
Netris Pharma is a clinical-stage company developing innovative therapeutics to improve treatment outcome for cancer patients, targeting resistance to both chemotherapy and immunotherapy.
About the solution
Their lead asset, NP137, is a first-in-class anti-Netrin1 monoclonal antibody currently investigated in a randomized phase II in Endometrial and Cervical cancers as well as in 5 exploratory trials.
Key information
– Therapeutic areas: Oncology and Women Health
– Based in: Lyon (FRANCE)
– Employees: 11 – 50
– Created in: 2008
